Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity

Semaglutide is a glucagon-like peptide-1 receptor agonist which has been shown to reduce body weight and improve health status in patients with obesity related heart failure with preserved ejection fraction in the STEP-HFpEF Program [1]. Semaglutide was adminstered once weekly as subcutaneous injection. The medication has been approved for long term weight management and has been shown to produce major weight loss in overweight and obese persons. It has favourable effects on cardiometabolic risk. Semaglutide reduces C-Reactive Protein level, systolic blood pressure and NT-proBNP level in patients with obesity and heart failure with preserved ejection fraction.

Reference

1. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC; STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25. PMID: 37622681.